BUCHANG PHARMA(SH:603858)2024-10-28 07:51Financial Performance - The company's operating revenue for Q3 2024 was ¥3,082,731,287.14, representing a year-over-year increase of 1.89%[2] - The net profit attributable to shareholders for Q3 2024 was ¥81,446,549.20, a decrease of 54.50% compared to the same period last year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2024 was ¥137,918,290.19, down 27.95% year-over-year[2] - The basic earnings per share for Q3 2024 was ¥0.0756, reflecting a decline of 53.28% compared to the previous year[2] - Total operating revenue for the first three quarters of 2024 was approximately ¥8.51 billion, a decrease of 14.7% compared to ¥9.98 billion in the same period of 2023[14] - Net profit for the first three quarters of 2024 was approximately ¥217.88 million, a significant decline of 73.8% compared to ¥831.23 million in 2023[15] - The company’s total profit for the first three quarters was approximately ¥501.85 million, a decrease of 53.6% from ¥1.08 billion in 2023[15] - Basic earnings per share for the first three quarters of 2024 were ¥0.2870, down from ¥0.8364 in the same period of 2023[15] Assets and Liabilities - Total assets at the end of Q3 2024 amounted to ¥20,148,869,033.65, down 3.56% from the end of the previous year[3] - As of September 30, 2024, the total assets of Shandong Buchang Pharmaceutical Co., Ltd. amounted to CNY 20,148,869,033.65, a decrease from CNY 20,892,297,542.28 at the end of 2023, representing a decline of approximately 3.55%[12][13] - The company's current assets totaled CNY 7,550,036,870.44, down from CNY 8,280,959,838.31, indicating a decrease of about 8.80%[12] - Total liabilities amounted to CNY 9,345,462,468.44, a slight decrease from CNY 9,516,288,169.00, representing a decline of about 1.80%[13] - The company's equity attributable to shareholders decreased to CNY 11,161,116,645.73 from CNY 11,616,993,595.29, indicating a decrease of approximately 3.92%[13] - Long-term borrowings increased significantly to CNY 2,783,646,229.72 from CNY 2,097,785,503.89, reflecting an increase of about 32.70%[13] - The company reported a decrease in total current liabilities to CNY 6,080,370,191.43 from CNY 6,856,045,867.35, a decline of approximately 11.27%[12] - The company’s total non-current liabilities increased to CNY 3,265,092,277.01 from CNY 2,660,242,301.65, representing an increase of about 22.73%[13] Cash Flow and Expenses - The net cash flow from operating activities for the year-to-date period was ¥701,464,029.30, showing a significant improvement compared to the previous period[5] - Cash flow from operating activities generated a net amount of approximately ¥701.46 million, a turnaround from a negative cash flow of ¥411.80 million in the same period last year[16] - Cash and cash equivalents at the end of the period increased to approximately ¥957.30 million, compared to ¥473.82 million at the end of the same period in 2023[17] - The company's financial expenses increased to approximately ¥89.98 million, up from ¥64.81 million in the previous year[14] - The company reported a decrease in sales expenses to approximately ¥3.27 billion, down 32.4% from ¥4.84 billion in the previous year[14] Research and Development - Research and development expenses increased to approximately ¥180.20 million, up 19.4% from ¥151.01 million in the previous year[14] Non-Recurring Gains and Losses - Non-recurring gains and losses for Q3 2024 totaled -¥56,471,740.99, with significant contributions from government subsidies and asset disposal losses[4]